ASKA Pharmaceutical Holdings: Supplementary information for the fiscal Q1 financial statement for March 2025.
ASKA Pharmaceutical Holdings: Short message of Q1 financial results for March 2025 (consolidated, Japanese standard).
ASKA Pharmaceutical Holdings: Extraordinary Report
ASKA Pharmaceutical Holdings: Confirmation letter
ASKA Pharmaceutical Holdings: Security Report - Third Quarter (April 1, 2023 - March 31, 2024)
ASKA Pharmaceutical Holdings: Supplementary material for the financial results report for the fiscal year ending 2024/3
ASKA Pharmaceutical Holdings: Summary of Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
Asuka Pharmaceutical Holdings: Confirmation
Asuka Pharmaceutical Holdings: Quarterly Report - 3rd Quarter (2023/10/01 - 2023/12/31)
ASKA Pharmaceutical Holdings: Supplementary material on financial results for the 3rd quarter of the fiscal year ending 2024/3
ASKA Pharmaceutical Holdings: Summary of Financial Results for the 3rd Quarter of the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
ASKA Pharmaceutical Holdings: Confirmation letter
ASKA Pharmaceutical Holdings: Quarterly Report - 3rd Quarter 2nd Quarter (2023/07/01 - 2023/09/30)
ASKA Pharmaceutical Holdings: Supplementary information on financial results report for the 2nd quarter of the fiscal year ending March 31, 2024
ASKA Pharmaceutical Holdings: Notice Concerning Dividends from Surplus Funds (Interim Dividend/Dividend Increase) and Revision (Increase) of Year-end Dividend Forecast
ASKA Pharmaceutical Holdings: Summary of Financial Results for the 2nd Quarter of the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
ASKA Pharmaceutical Holdings: Notice regarding revisions to earnings forecasts for the fiscal year ending March 31, 2024
ASKA Pharmaceutical Holdings: Confirmation letter
ASKA Pharmaceutical Holdings: Quarterly Report - Third Quarter (2023/04/01 - 2023/06/30)
ASKA Pharmaceutical Holdings: Supplementary material to the financial results report for the first quarter of the fiscal year ending March 31, 2024
No Data
No Data